A subscription to JoVE is required to view this content. Sign in or start your free trial.
This protocol presents a standardized method to grow VX2 cells in culture and to create an orthotopic VX2 model of endometrial cancer with retroperitoneal lymph node metastases in rabbits. Orthotopic endometrial cancer models are important for the pre-clinical study of novel imaging modalities for the diagnosis of lymph node metastases.
Endometrial cancer is the most common gynecologic malignancy in North America and the incidence is rising worldwide. Treatment consists of surgery with or without adjuvant therapy depending on lymph node involvement as determined by lymphadenectomy. Lymphadenectomy is a morbid procedure, which has not been shown to have a therapeutic benefit in many patients, and thus a new method to diagnose lymph node metastases is required. To test novel imaging agents, a reliable model of endometrial cancer with retroperitoneal lymph node metastases is needed. The VX2 endometrial cancer model has been described frequently in the literature; however, significant variation exists with respect to the method of model establishment. Furthermore, no studies have reported on the use of cultured VX2 cells to create this model as only cells propagated in vivo have been previously used. Herein, we present a standardized surgical method and post-operative monitoring method for the establishment of the VX2 endometrial cancer model and report on the first use of cultured VX2 cells to create this model.
Endometrial cancer, or cancer of the lining of the uterus, is the second most common gynecologic malignancy worldwide and the most common malignancy in developed nations1. The incidence of endometrial cancer has steadily increased, rising by 2.3% per year between 2005-2013 with a corresponding 2.2% increase in mortality1,2,3. The diagnosis of lymph node metastases is paramount as the presence of positive lymph nodes is a strong negative predictor of survival4,5,6
Deep abdominal wall closure: Identify the apex of the peritoneal incision and grasp the peritoneum, rectus muscle and fascia with tissue forceps.All animal studies were conducted in Animal Resource Center (ARC) approved facilities of the University Health Network and in accordance with approved animal use and care protocols (AUP #3994/#4299). VX2 cell line was obtained from Dr. Aken’s Lab at the University Health Network.
1. Creation of in vitro VX2 cell line
Twenty-eight rabbits were used for the creation of the endometrial cancer model. Rabbits had an average weight of 2.83 kg (2.71-3.58 kg) at the time of experiment. Uterine tumors successfully grew in 21 rabbits for an overall model success rate of 75%. Prior to the inclusion of uterine suturing in the protocol, the success rate was 57% compared to 81% after uterine suturing was added. Uterine suturing was added to the protocol after the 7th rabbit in response to the initial low.......
Herein, we have reported a standardized surgical method for the establishment of a VX2 endometrial cancer model and reported on the first use of cultured VX2 cells to create this model. The tumor take rate of 75% is lower than the 100% percent rate previously reported in the literature35,37,53,56; however, thw 90% rate of pathologically confirmed lymph node metastases is consistent with previou.......
This study was funded by the Terry Fox Research Institute (PPG#1075), the Canadian Institute of Health Research (Foundation Grant #154326), the Canadian Cancer Society Research Institute (704718), Natural Sciences and Engineering Research Council of Canada, Сanada Foundation for Innovation and Princess Margaret Cancer Foundation.
I would like to thank Dr. Marguerite Akens for providing the initial VX2 cells for the establishment of the initial VX2 model and the frozen VX2 tumor blocks. I would like to thank Marco DiGrappa for helping to perform initial VX2 cell culture experiments and Lili Ding for helping with VX2 cell culture.
....Name | Company | Catalog Number | Comments |
11-blade scalpel, Sterile, Disposible | Aspen Surgical (VWR) | 80094-086 | |
22-gague ear vein catheter | CDMV | 14332 | |
3-0 absorbable poly-filament suture (Polysorb) | Covidien | 356718 | |
3-0 braided absorbable suture (Polysorb) | Covidien | 356718 | |
70uM cell strainer, Individually wrapped, Nylon | Falcon | 352350 | |
Acepromazine (Atravet) | CDMV | 1047 | |
Betadine soap (Poviodone iodine 7.5%) | CDMV | 4363 | |
Betadine solution (Poviodone iodine 10%) | UHN Stores | 457955 | |
Buprenorphine | McGill University | ||
Cefazolin | UHN in-patient pharmacy | No Cat # Needed | |
Chlorhexidine solution | CDMV | 119872 | |
Corning BioCoatCellware, Collagen Type I, 100mm dishes | Corning | 354450 | brand not important |
Corning BioCoatCellware, Collagen Type I, 24-well plates | Corning | 354408 | brand not important |
Corning BioCoatCellware, Collagen Type I, 6-well plates | Corning | 354400 | brand not important |
Corning Matrigel Basement Membrane Matrix, *LDEV-free, 10 mL | Corning | 354234 | |
DMEM/HAM F12 1:1 | Life Technologies | 11320 | brand not important |
DMSO | Caledon Lab Chem | 1/10/4100 | |
Enrofloxacin (Baytril injectable) | CDMV | 11242 | |
Falcon Tube | Corning Centri-Star | 430828 | |
Fetal Bovine Serum, Qualified, Canadian Origin, 500ml | Life Technologies | 12483020 | brand/source not important |
Isoflurane | UHN in-patient pharmacy | No Cat # Needed | |
Isohexol contrast | GE Healthcare | 407141210 | |
Meloxicam (Metacam 0.5%) | CDMV | 104674 | |
Normal Saline | House Brand (UofT Medstore) | 1011 | |
PBS | Multicell or Sigma | 331-010-CL or D8537-500mL | |
Penicillin/Streptomycin (100mL; 10000U Penicillin, 10000ug Streptomycin) | Corning-Cellgro | CA45000-652 | |
Sterile Hanks Balanced Salt Solution (-Ca++, -Mg++, -Phenol Red) | T.C.M.F (Dr Bristow) | 28-Jan-11 | |
Surgical Glue (Tissue Adhesive) | 3M Vetbond | 14695B | |
Trypsin (0.25%), Proteomics Grade | Sigma | T-6567-5X20UG | |
Trypsin-EDTA, 0.05%, 100ml | Wisent Inc | 325-542-EL | brand not important |
This article has been published
Video Coming Soon
ABOUT JoVE
Copyright © 2024 MyJoVE Corporation. All rights reserved